In addition, since PD1 blockades induce a strong anti-tumor function by modulating an immunometabolic program of myeloid cells with a crucial role in systemic antitumor response, myeloid-specific PD-1 targeting was proposed as a tool to improve cancer immunotherapy. Here, PDCD1 is linked to cancer.